Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Is raloxifene associated with lower risk of mortality in postmenopausal women with vertebral fractures after vertebroplasty?: a hospital-based analysis.

Su FM, Chen YC, Cheng TT, Lin WC, Lui CC.

BMC Musculoskelet Disord. 2015 Aug 19;16:209. doi: 10.1186/s12891-015-0670-7.

2.

The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status.

Adami S, Palacios S, Rizzoli R, Levine AB, Sutradhar S, Chines AA.

Climacteric. 2014 Jun;17(3):273-84. doi: 10.3109/13697137.2013.830605. Epub 2013 Nov 7.

PMID:
23937421
3.

Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.

Palacios S, de Villiers TJ, Nardone Fde C, Levine AB, Williams R, Hines T, Mirkin S, Chines AA; BZA Study Group.

Maturitas. 2013 Sep;76(1):81-7. doi: 10.1016/j.maturitas.2013.06.008. Epub 2013 Jul 18.

PMID:
23871271
4.

[Selective Estrogen Receptor Modulators (SERMs) for prevention and treatment of postmenopausal osteoporosis].

Birkhäuser M.

Ther Umsch. 2012 Mar;69(3):163-72. doi: 10.1024/0040-5930/a000269. Review. German.

PMID:
22403109
5.

The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women.

Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, Thabane L.

BMC Musculoskelet Disord. 2011 Sep 26;12:209. doi: 10.1186/1471-2474-12-209. Review.

6.

[Selective estrogen receptor modulators: focus on bazedoxifene].

Lello S.

Minerva Ginecol. 2011 Jun;63(3):305-14. Review. Italian. Erratum in: Minerva Ginecol. 2011 Dec;63(6):580.

PMID:
21654615
7.

Fracture prevention in postmenopausal women.

Vestergaard P, Mosekilde L, Langdahl B.

BMJ Clin Evid. 2011 May 3;2011. pii: 1109. Review.

8.

Patient characteristics and utilization of breast cancer screening or diagnostic procedures prior to initiation of raloxifene, bisphosphonates and calcitonin.

Foster SA, Whangbo A, Mitchell B, Muram D, Mershon JL, Kar R, Vedarajan G.

Curr Med Res Opin. 2010 Nov;26(11):2521-6. doi: 10.1185/03007995.2010.515456. Epub 2010 Sep 15.

PMID:
20843165
9.

Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer.

Ivergård M, Ström O, Borgström F, Burge RT, Tosteson AN, Kanis J.

Bone. 2010 Nov;47(5):966-74. doi: 10.1016/j.bone.2010.07.024. Epub 2010 Aug 3.

PMID:
20691296
10.

Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.

Duvernoy CS, Yeo AA, Wong M, Cox DA, Kim HM.

J Womens Health (Larchmt). 2010 Aug;19(8):1459-65. doi: 10.1089/jwh.2009.1687.

PMID:
20626269
11.

Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.

Pinkerton JV, Goldstein SR.

Menopause. 2010 May-Jun;17(3):642-53. doi: 10.1097/gme.0b013e3181c4f1d6. Review.

PMID:
20107426
12.

Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.

Lewiecki EM.

J Womens Health (Larchmt). 2009 Oct;18(10):1615-26. doi: 10.1089/jwh.2008.1086. Review.

PMID:
19857095
13.

Clinical and therapeutic aspects of osteoporosis.

Compston J.

Eur J Radiol. 2009 Sep;71(3):388-91. doi: 10.1016/j.ejrad.2008.04.063. Epub 2009 Aug 5. Review.

PMID:
19660883
14.

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

Kanis JA, Johansson H, Oden A, McCloskey EV.

Bone. 2009 Jun;44(6):1049-54. doi: 10.1016/j.bone.2009.02.014. Epub 2009 Feb 28.

PMID:
19254788
15.

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.

Cuzick J.

Expert Rev Anticancer Ther. 2008 Sep;8(9):1377-85. doi: 10.1586/14737140.8.9.1377.

PMID:
18759690
16.

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.

Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA.

J Bone Miner Res. 2008 Dec;23(12):1923-34. doi: 10.1359/jbmr.080710.

17.

Osteodensitometry in healthy postmenopausal women.

[No authors listed]

Prescrire Int. 2008 Apr;17(94):68-72.

PMID:
18536138
18.

Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.

Lee WL, Chao HT, Cheng MH, Wang PH.

Maturitas. 2008 Jun 20;60(2):92-107. doi: 10.1016/j.maturitas.2008.04.009. Epub 2008 Jun 4. Review.

PMID:
18534794
19.

Bazedoxifene: bazedoxifene acetate, TSE 424, TSE-424, WAY 140424.

[No authors listed]

Drugs R D. 2008;9(3):191-6.

PMID:
18457472
20.

Association between baseline values of bone turnover markers and bone mineral density and their response to raloxifene treatment in Japanese postmenopausal women with osteoporosis.

Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.

Endocr J. 2008 Mar;55(1):41-8. Epub 2008 Jan 10.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk